Our company
Overview
Our Strategy
Leadership team
Board of Directors
Careers
Events
Certifications
Technology
What are Autoantibodies ?
ImmunoINSIGHTS Platform
Publications
Biotech/Pharma
Biomarker Discovery
Targeted Panels & Arrays
Bioinformatics & Data Science
Applications
Autoimmune Disease Biomarkers
Immuno-oncology Biomarkers
Infectious Disease Biomarkers
Resources
Investors
Overview
Regulatory news
Share price
Analyst research
Results, reports & presentations
Shareholder analysis
Company documents
AIM Rule 26
Corporate governance
NOMAD & advisor contacts
Contact us
Resources
Therapeutic areas
All
Autoimmune diseases
General
Immuno-oncology
Infectious diseases
News
Partnerships
Uncategorised
Diseases
Systemic lupus erythematosus (SLE)
Sjörgen’s syndrome
Systemic sclerosis (SSc)
Rheumatoid arthritis (RA)
Checkpoint inhibitors
Bispecifics
CAR-T
CART-NK
EarlyCDT Lung Cancer
COVID19
Long-Covid
Filter by type
annual report
autoantibodies
Brochure
cancer
checkpoint inhibitors
Company News
company update
Diagnostics
immunotheraphies
Indeterminate Pulmonary Nodules
Poster
Publication
Webinar
23 May 2024
22 May 2024
21 May 2024
23 April 2024
18 April 2024
6 March 2024
5 March 2024
29 February 2024
12 December 2023
1 December 2023
30 November 2023
Oncimmune’s CEO, Martin Gouldstone speaks to Vox Market about the company’s new strategy progress.
Read Article
